ARMC6 Inhibitors

ARMC6 inhibitors encompass a range of compounds that indirectly facilitate the degradation or destabilization of the ARMC6 protein through various intracellular pathways. Bortezomib, a proteasome inhibitor, can indirectly lead to the degradation of ARMC6 by causing an accumulation of polyubiquitinated proteins, including potentially misfolded ARMC6, which can trigger cellular responses aimed at degrading these proteins. Similarly, MG-132 prevents the proteasomal degradation of polyubiquitinated proteins, which may include ARMC6. This accumulation could lead to a cellular environment that induces the misfolding and subsequent degradation of ARMC6.

Lenalidomide, thalidomide, and pomalidomide, all of which bind to cereblon, modulate the substrate specificity of E3 ubiquitin ligases. This modulation has the potential to change the ubiquitination pattern of ARMC6, leading to its degradation. On the other hand, autophagy inhibitors like chloroquine, hydroxychloroquine, 3-methyladenine, and spautin-1 can lead to the accumulation of cellular components, including ARMC6. This can induce stress responses within the cell that target ARMC6 for degradation.